Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02957968
Title Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Virginia Commonwealth University
Indications

Her2-receptor negative breast cancer

Therapies

Decitabine + Pembrolizumab

Cyclophosphamide + Doxorubicin

Carboplatin + Paclitaxel

Paclitaxel

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.